Less Lumping, Smarter Splitting: Genomics and Metabolomics of Systemic Steroid Response in Bronchopulmonary Dysplasia
更少的结块,更智能的分裂:支气管肺发育不良全身类固醇反应的基因组学和代谢组学
基本信息
- 批准号:10053125
- 负责人:
- 金额:$ 22.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-01 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcidsAddressAdrenal Cortex HormonesAdverse effectsAdverse eventAffectAgeAllelesBiological MarkersBirthBronchopulmonary DysplasiaCandidate Disease GeneChildChildhoodCitric AcidClinicalCorticotropin-Releasing Hormone ReceptorsDataData SetDevelopmentDexamethasoneDiseaseDoseDrug usageEarly treatmentEnrollmentEpidemicExhibitsExposure toFDA approvedFutureGenesGeneticGenetic PolymorphismGenomeGenomicsGestational AgeGluconatesGoalsGrowthHomeostasisHydrocortisoneHypertensionIncidenceInfantKnowledgeLeadLifeLiteratureLungLung diseasesLung infectionsMechanical ventilationMethodsMissionModernizationNational Institute of Child Health and Human DevelopmentNeurodevelopmental ImpairmentObstetric pharmacologyOrphan DrugsOutcomeOxygen Therapy CarePatient CarePatientsPharmaceutical PreparationsPharmacogenomicsPharmacologyPharmacometabolomicsPharmacotherapyPhenotypePhysiologic calcificationPlasmaPopulationPrecision therapeuticsPregnancyPremature BirthPremature InfantPublishingPulmonary Valve InsufficiencyRegimenResearchResearch Project GrantsRespiratory physiologyRiskRoleSerumSeveritiesSiteSteroid therapySteroidsTherapeuticToxic effectUnited StatesUrineadverse event riskclinical efficacyclinical practicecohortdrug efficacyexperimental studygenetic variantgenome sequencinggenomic biomarkerhigh riskhospital readmissionimprovedindividualized medicineinter-individual variationmetabolomemetabolomicsmultidisciplinaryneonatenovelpatient populationpediatric pharmacologypersonalized therapeuticpopulation basedprecision drugsprecision medicinepressurepreventprogramsprospectivepulmonary functionrecruitrespiratoryresponders and non-respondersresponseresponse biomarkerrisk benefit ratioside effectsteroid metabolismtoolwhole genome
项目摘要
Project Summary/Abstract
2.5 million infants are born at less than 32 weeks gestation worldwide every year, with approximately 75,000 of
them born in the US. Many of these preterm infants develop a severe form of lung disease called
Bronchopulmonary Dysplasia (BPD), which manifests as poor lung function requiring prolonged mechanical
ventilation and oxygen therapy, and predisposing to poorer neurodevelopmental outcomes. In addition, these
children exhibit increased fragility to lung infections and often require hospital readmissions in the first year of
life. Severe Bronchopulmonary Dysplasia is one of the most important pediatric pulmonary disorder in the
United States, increasing in incidence as increasing numbers of extremely preterm infants survive to leave the
ICU.
One commonly used drug therapy for BPD is systemic steroids, including the corticosteroids dexamethasone
and hydrocortisone, which produces variable and unpredictable short term pulmonary benefit, but are
associated with neurodevelopmental impairment and other important side effects such as growth stunting,
hypertension and decreased bone mineralization. Given the variable clinical efficacy and high risk for adverse
effects, it is important to identify a group of infants with BPD who will benefit the most from steroid therapy,
making the risk of adverse events more acceptable. There are functionally important genetic variants known to
impact steroid metabolism and response in similar patient populations, so we know that variability in steroid
response likely has, in part, genetic underpinnings.
In a prospectively recruited multi-site cohort (N=150), we will assess genomic and metabolomic markers which
correlate with steroid response in BPD. We will capitalize on prior published knowledge and pilot data, as well
as take an agnostic approach, to identify genomic biomarkers of steroid response among preterm infants
treated with systemic dexamethasone or hydrocortisone for BPD. We will also compare the urine and plasma
pharmacometabolome between steroid responders and non-responders to look for pre-treatment or early
treatment markers of drug efficacy. The overall goal of the research program is to elucidate genomic and
metabolomics biomarkers of clinical response, as a mechanism to identify a group of infants with the most
favorable risk to benefit ratio, moving the field of BPD treatment towards precision medicine. This project fits
well with the mission of the NICHD Obstetric and Pediatric Pharmacology branch, because it addresses a
severe pediatric disease with highly variable and unpredictable drug response (efficacy and toxicity). The
systematic application of modern pharmacology research tools will allow the identification of certain preterm
infants, either a priori or early in the treatment course, who will have clinical benefit >>toxicity risk, allowing for
personalized therapeutics in this group of infants.
项目摘要/摘要
全球每年有250万名婴儿在怀孕不到32周时出生,其中约7.5万人
他们出生在美国。这些早产儿中的许多人会患上一种严重的肺部疾病,称为
支气管肺发育不良(BPD),表现为肺功能低下,需要长期机械治疗
通风和氧疗,并容易导致较差的神经发育结果。此外,这些
儿童表现出对肺部感染的脆弱性增加,通常需要在#年的第一年重新住院。
生活。摘要严重的支气管肺发育不良是儿童肺部疾病中最重要的疾病之一。
美国,随着越来越多的极早产儿存活下来离开美国,发病率不断上升
重症监护室。
治疗bpd的一种常用药物是全身类固醇,包括皮质类固醇地塞米松。
和氢化可的松,它产生可变和不可预测的短期肺部益处,但
与神经发育障碍和其他重要的副作用有关,如生长发育迟缓,
高血压和骨矿化减少。考虑到不同的临床疗效和不良反应的高风险
重要的是,确定一组患有BPD的婴儿谁将从类固醇治疗中受益最大,
使不良事件的风险更容易被接受。已知有一些功能上重要的遗传变异
在相似的患者群体中影响类固醇代谢和反应,所以我们知道类固醇的变异性
这种反应可能在一定程度上有基因基础。
在一个前瞻性招募的多点队列中(N=150),我们将评估哪些基因组和代谢标记
与BPD的激素反应相关。我们还将利用之前发布的知识和试点数据
采取不可知的方法,确定早产儿激素反应的基因组生物标记物
全身应用地塞米松或氢化可的松治疗BPD。我们还会比较尿液和血浆
激素应答者和无应答者之间的药物代谢谱寻找治疗前或早期
药物疗效的治疗标志物。该研究计划的总体目标是阐明基因组和
代谢组学生物标志物的临床反应,作为识别一组婴儿最多的机制
良好的风险收益比,将BPD治疗领域推向精准医学。这个项目很适合
NICHD产科和儿科药理学分会的使命,因为它涉及一个
具有高度可变和不可预测的药物反应(疗效和毒性)的严重儿科疾病。这个
现代药理学研究工具的系统应用将使某些早产的识别成为可能
先天或疗程早期的婴儿,他们将具有临床益处&>;毒性风险,允许
这组婴儿的个人化治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tamorah R Lewis其他文献
Tamorah R Lewis的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tamorah R Lewis', 18)}}的其他基金
Ontogeny and Genetics of NSAID Dose-Exposure Relationship in Preterm Infants
早产儿 NSAID 剂量暴露关系的个体发育和遗传学
- 批准号:
10247583 - 财政年份:2018
- 资助金额:
$ 22.37万 - 项目类别:
Ontogeny and Genetics of NSAID Dose-Exposure Relationship in Preterm Infants
早产儿 NSAID 剂量暴露关系的个体发育和遗传学
- 批准号:
9792266 - 财政年份:2018
- 资助金额:
$ 22.37万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 22.37万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 22.37万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 22.37万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 22.37万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 22.37万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 22.37万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 22.37万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 22.37万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 22.37万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 22.37万 - 项目类别:
Research Grant